Quantum Biopharma (QNTM) Income from Continuing Operations (2019 - 2026)
Quantum Biopharma (QNTM) posted Income from Continuing Operations of 10764405.0 for Q1 2026, up 567.87% sequentially from 2300748.0 in Q4 2025, and up 102.33% YoY from 5320290.0 in Q1 2025.
Quantum Biopharma (QNTM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Quantum Biopharma (QNTM) has 8 years of Income from Continuing Operations data on file, last reported at 10764405.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 102.33% year-over-year to 10764405.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13237486.0 (up 350.5% YoY) and the FY2025 annual result came in at 15460437.0, up 4.38% from the prior year.
- Income from Continuing Operations grew to 10764405.0 in Q1 2026 per QNTM's latest filing, from 2300748.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 10764405.0 in Q1 2026, with the low at 2300748.0 in Q4 2025.
- Average Income from Continuing Operations over 5 years is 1630170.92, with a median of 67280.5 recorded in 2024.
- Year-over-year, Income from Continuing Operations sank 259.4% in 2024 and jumped 4364.41% in 2025.
- Quantum Biopharma's Income from Continuing Operations stood at 5633288.0 in 2022, then sank by 138.71% to 2180677.0 in 2023, then rose by 4.01% to 2093300.0 in 2024, then dropped by 9.91% to 2300748.0 in 2025, then soared by 567.87% to 10764405.0 in 2026.
- Business Quant data shows QNTM's Income from Continuing Operations at 10764405.0 in Q1 2026, 2300748.0 in Q4 2025, and 22097.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | 74.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -14.46 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 227.36 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.03 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -4.45 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 378.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 205.99 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -453.82 Mn |
| 10 | Quantum Biopharma | 15.08 Mn | 8.50 Mn | - | 10.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.76 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -22,097.00 |
| Jun 30, 2025 | 4.80 Mn |
| Mar 31, 2025 | 5.32 Mn |
| Dec 31, 2024 | -2.09 Mn |
| Sep 30, 2024 | -186,485.00 |
| Jun 30, 2024 | -112,464.00 |
| Mar 31, 2024 | -178,345.00 |
| Sep 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | 111,887.00 |
| Mar 31, 2022 | 5.63 Mn |
| Jun 30, 2021 | -12.71 Mn |
| Mar 31, 2021 | 9.78 Mn |
| Sep 30, 2020 | -13.18 Mn |
| Jun 30, 2020 | -3.53 Mn |
| Mar 31, 2020 | 3.03 Mn |
| Dec 31, 2019 | -11.59 Mn |
| Sep 30, 2019 | -8.50 Mn |
| Jun 30, 2019 | -5.94 Mn |